A

small biotech that got hammered by investors when it unveiled disappointing results from a Phase 2 clinical trial of its Alzheimer’s drug last spring will report better news on Sunday. After following patients with advanced Alzheimer’s for an additional two weeks, Neurotrope (NTRP) found that the improved cognitive scores of those on a low dose of the compound, bryostatin, were large enough compared to patients in the control group to come within a whisker of statistical significance. And in subsets of the low-dose patients, the  cognitive improvement cleared that statistical bar.

All of the follow-on analyses, which Neurotrope president and chief scientific officer Dr. Daniel Alkon will present at the Sachs’ Neuroscience Innovation Forum in San Francisco, were pre-specified in the statistical plan for the clinical trial, not post hoc — which is considered statistically suspect.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy